Verrica Pharmaceuticals Q3 net loss narrows

Verrica Pharmaceuticals

14/11/2025 21:16

Overview

Verrica Q3 revenue at $14.3 mln, driven by YCANTH and collaboration revenue

Net loss for Q3 narrows to $0.3 mln from $22.9 mln last year

Received $10 mln milestone payment for YCANTH approval in Japan

Outlook

Verrica expects to launch YCANTH Rx in Q4 2025

Company plans first patient enrollment for YCANTH Phase 3 in US by end of 2025

Verrica receives EMA feedback supporting YCANTH registration in Europe

Result Drivers

YCANTH SALES - Revenue driven by $3.6 mln from YCANTH sales and increased applicator units dispensed

COLLABORATION REVENUE - $10.7 mln in collaboration revenue, including $10 mln milestone from Torii for YCANTH approval in Japan

REGULATORY MILESTONES - Positive feedback from FDA and EMA for YCANTH and VP-315 development programs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$274,000
Q3 Income from Operations
$1.63 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Verrica Pharmaceuticals Inc is $19.00, about 79.6% above its November 13 closing price of $3.87

Press Release: ID:nGNX3dcBGf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)